New Factor XIa Inhibitor Cuts Stroke Risk With Lower Bleeding: Phase III Win
Alex So, Associate Director Strategy and Digitalisation China at Merck Group, posted on LinkedIn:
”Rather than a discouraging attempt that the quoted video may suggest, it is delightful to know the factor XIa inhibitor’s potential to reduce stroke risk in patients who have had a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, as reported by its latest phase III trial for secondary stroke prevention.
Factor XIa can activate Factor IX, amplifying thrombin generation of the clotting process. As an anticoagulation strategy, the inhibition has less impact on clot stabilisation in response to injury, i.e., a lower risk of bleeding. It might be worth rementioning the siRNA drug that silences the gene producing antithrombin, a mechanism in this field applicable to haemophilia as discussed in a prior post.
The milestone success, which enables continued efforts to develop a better blood thinner despite a somewhat reduced scope and to investigate Factor XIa as a target, is encouraging.
Non-business-related therapeutics posting. Consult practitioners for medication needs.”
Stay updated with Hemostasis Today.
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke
-
Feb 26, 2026, 15:15Shannon Farmer: What Happens to Vital Signs Pre and Post 1-Unit and 2-Unit RBC Transfusion?
-
Feb 26, 2026, 15:08Emmanuel J Favaloro: When Is A ‘Subtype’ of VWD Not Really VWD?
-
Feb 26, 2026, 15:03Gregory Piazza: Importance of Recognizing PE As A Wide Spectrum of Presentations and Greater Range of Adverse Outcomes
-
Feb 26, 2026, 14:57Abdulla A. Damluji: Sex As An Effect Measure Modifier Between Frailty and Outcomes in AMI Patients
-
Feb 26, 2026, 14:48Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban’s Role in LVT
-
Feb 26, 2026, 14:44Wolfgang Miesbach: Synovitis and Haemophilia in Focus at GTH2026
-
Feb 26, 2026, 14:40Al-Ola Abdallah: How Much Does It Cost to Publish in Hematology and Oncology Journals